Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kura OncologyFRA:KUR -5.38%36 Forward Dividend Yield % is 0.00% as of Jul. 14, 2026. GuruFocus rates FRA:KUR with a GF Score™ of 36/100. The stock has 7 warning signs investors should review. Among 148 Biotechnology companies, Kura Oncology ranks worse than 675675% on this metric.
As of today (2026-07-14), the Forward Annual Dividend Yield of Kura Oncology is 0.00%.
As of today (2026-07-14), the Trailing Annual Dividend Yield of Kura Oncology is 0.00%.
FRA:KUR's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.26 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Kura Oncology (FRA:KUR) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Kura Oncology Forward Dividend Yield % Related Terms
FRA:KUR vs REPL, AVTX, SANA: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Kura Oncology's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kura Oncology Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kura Oncology's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Kura Oncology's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Kura Oncology (FRA:KUR) has a Forward Dividend Yield % of 0.00% as of Jul. 14, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Kura Oncology and its competitors. According to the industry distribution chart, Kura Oncology ranks #999999 out of 148 companies in the Biotechnology industry.
Is Kura Oncology's Forward Dividend Yield % too high?
Kura Oncology's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Kura Oncology ranks #999999 out of 148 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kura Oncology has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Kura Oncology's Forward Dividend Yield % compare to REPL and AVTX?
According to the Biotechnology industry distribution chart, Kura Oncology ranks #999999 out of 148 companies for Forward Dividend Yield %. This places Kura Oncology in the lower half of its industry. The industry median Forward Dividend Yield % is 1.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.26, based on 148 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Kura Oncology and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kura Oncology's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kura Oncology stock overvalued right now?
Kura Oncology (FRA:KUR) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Kura Oncology's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Kura Oncology (FRA:KUR), the current Forward Dividend Yield % is 0.00% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
36GF Score
Get the complete analysis for FRA:KUR
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KUR has been successfully added to your 
